Related Experiment Video
Updated: Aug 14, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer
Carolin Grunwald1, Michael Koslowski, Tülin Arsiray
1Department of Internal Medicine III, Johannes Gutenberg-University, Langenbeckstr. 1, 55131 Mainz, Germany, and University Hospital Ghent, Belgium.
Abstract:
Cancer/germline (CG) antigens represent promising targets for widely applicable mono- and multiantigen cancer vaccines for nonsmall cell lung cancer (NSCLC). Since little is known about their composite expression in this tumor type, we analyzed 7 CG genes (MAGE-A3, NY-ESO-1, LAGE-1, BRDT, HOM-TES-85, TPX-1 and LDHC) in 102 human NSCLC specimens. About 81% of NSCLC express at least 1 and half of the specimen at least 2 CG genes. Activation of most of these genes occurs more frequently in squamous cell cancer than in adenocarcinomas. Even though we found all genes but one to be regulated by genomic methylation, not all of them are co-expressed. In particular, combining CG genes not localized on the X-chromosome may provide effective treatment for an extended number of patients.
Insights
Cancer/germline (CG) antigens are promising targets for nonsmall cell lung cancer (NSCLC) vaccines. Most NSCLC express multiple CG genes, suggesting combination therapies could benefit more patients.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Cancer/germline (CG) antigens are potential targets for cancer vaccines in nonsmall cell lung cancer (NSCLC).
- Limited data exists on the combined expression of CG antigens in NSCLC.
- Understanding CG antigen expression is crucial for developing effective NSCLC immunotherapies.
Purpose of the Study:
- To analyze the expression of seven CG genes in human NSCLC specimens.
- To determine the frequency and patterns of CG gene expression in different NSCLC subtypes.
- To explore the potential for combination CG antigen-based therapies in NSCLC.
Main Methods:
- Analysis of 7 CG genes (MAGE-A3, NY-ESO-1, LAGE-1, BRDT, HOM-TES-85, TPX-1, LDHC) in 102 NSCLC specimens.
- Assessment of gene expression patterns and correlation with NSCLC subtypes (squamous cell carcinoma vs. adenocarcinoma).
- Investigation of genomic methylation's role in CG gene regulation.
Main Results:
- 81% of NSCLC specimens expressed at least one CG gene; 50% expressed at least two.
- CG gene activation was more frequent in squamous cell carcinoma than in adenocarcinomas.
- Most analyzed CG genes were regulated by genomic methylation, but not all were co-expressed.
Conclusions:
- A significant proportion of NSCLC patients express multiple CG antigens, supporting the development of multiantigen vaccines.
- Combining CG genes not located on the X-chromosome may broaden treatment applicability for NSCLC patients.
- Targeting specific combinations of CG antigens holds promise for more effective NSCLC treatment strategies.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Cancers Originate from Somatic Mutations in a Single Cell
